Hyperprogression on Immunotherapy: Identifying Patients Whose Tumours Accelerate Under Checkpoint Blockade
This perspective synthesizes evidence on hyperprogression -- paradoxical rapid tumour growth following immune checkpoint blockade -- defining its characteristics, estimated frequency, and prognostic implications. The phenomenon highlights the urgent need for biomarkers that can identify patients at risk of hyperprogression before treatment initiation. For diagnostic laboratories, this underscores that companion diagnostics for immunotherapy must go beyond predicting benefit to also flagging potential harm.
The original study
The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.
- Authors
- Sabio E, Chan TA
- Journal
- Genome medicine
- Type
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
- PMID
- 31340855
Original abstract
Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective, we synthesize and summarize some important issues surrounding hyperprogression, defining characteristics, prognostic implications, and controversies.